[ENDP] Endo International plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 16.27 Change: 0.5 (3.17%)
Ext. hours: 16.25 Change: -0.02 (-0.12%)

chart ENDP

Refresh chart

Strongest Trends Summary For ENDP

ENDP is in the long-term down -80% below S&P in 1 year and down -97% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women?s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men?s and women?s health, and prostate health. The company?s products also inc

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-1.55% Sales Growth - 4 Quarters -15.23% Sales Growth - Q/Q-10.73% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.55% ROE-8.7% ROI-3.62%
Current Ratio1.55 Quick Ratio1.37 Long Term Debt/Equity2.86 Debt Ratio0.83
Gross Margin49.62% Operating Margin-27.98% Net Profit Margin-11.54% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities996.86 M Cash From Operating Activities-930.48 M Gross Profit329.86 M
Net Profit-89.81 M Operating Profit45.75 M Total Assets14.15 B Total Current Assets5.33 B
Total Current Liabilities3.44 B Total Debt5.39 B Total Liabilities10.01 B Total Revenue714.13 M
Technical Data
High 52 week18.3 Low 52 week2.23 Last close3.49 Last change3.87%
RSI56.72 Average true range0.35 Beta0.74 Volume2.59 M
Simple moving average 20 days0.37% Simple moving average 50 days12.06% Simple moving average 200 days-43.02%
Performance Data
Performance Week-6.43% Performance Month-16.9% Performance Quart-0.29% Performance Half-53.59%
Performance Year-80.07% Performance Year-to-date-52.19% Volatility daily6.16% Volatility weekly13.76%
Volatility monthly28.21% Volatility yearly97.72% Relative Volume179.67% Average Volume7.95 M
New High New Low

News

2019-11-08 07:52:58 | Edited Transcript of ENDP earnings conference call or presentation 5-Nov-19 12:30pm GMT

2019-11-06 14:34:00 | Endo CEO to step down when successor is named

2019-11-05 15:56:49 | Endo begins search for a new CEO

2019-11-05 10:42:03 | Endo ENDP Q3 Earnings & Revenues Beat Estimates, Down Y/Y

2019-11-05 05:30:00 | Endo International Plc to Host Earnings Call

2019-11-04 18:45:11 | Endo International ENDP Q3 Earnings and Revenues Top Estimates

2019-11-04 17:14:11 | UPDATE 1-Endo quarterly profit beat fueled by sterile injectables

2019-11-04 16:33:12 | Endo posts smaller third-quarter loss, CEO to retire

2019-11-04 16:15:00 | Endo Implements CEO Succession Plan

2019-11-04 16:15:00 | Endo Reports Third-Quarter 2019 Financial Results

2019-11-01 07:05:00 | 'The Trend Is Your Friend'

2019-10-29 10:33:02 | Earnings Preview: Endo International ENDP Q3 Earnings Expected to Decline

2019-10-28 12:03:59 | Is Endo International plc ENDP Going To Burn These Hedge Funds ?

2019-10-28 07:30:00 | Endo Aesthetics Launches New Campaign Elevating Artistry Through Scientific Innovation

2019-10-25 07:30:00 | Endo Presents New XIAFLEX® collagenase clostridium histolyticum Data at the 2019 Fall Meeting of the Sexual Medicine Society of North America SMSNA

2019-10-24 14:48:33 | Why Are Endo Shares Trading Lower?

2019-10-24 07:30:00 | Endo Presents Data on the Use of a Standing MRI for the Evaluation of Cellulite at the American Society for Dermatologic Surgery ASDS Annual Meeting

2019-10-23 07:30:00 | Movapo® apomorphine hydrochloride for Patients with Advanced Parkinson's Disease Now Reimbursed in Most Canadian Provinces

2019-10-22 11:29:10 | Jim Cramer Gives His Take On AMD, Merck And More

2019-10-21 09:58:21 | Major indexes in the green, tech mixed

2019-10-21 08:08:54 | UPDATE 9-Drug firms avert landmark opioid trial as talks on $48-bln settlement set to resume

2019-10-18 12:30:25 | UPDATE 6-Opioid settlement talks fail, landmark trial expected Monday

2019-10-18 07:00:00 | Judge's unorthodox approach has huge opioid settlement within reach

2019-10-14 19:04:11 | Johnson & Johnson's JNJ Legal Problems Continue to Worry Investors

2019-10-07 06:30:00 | Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products

2019-10-03 11:16:03 | J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

2019-10-03 07:37:10 | When Can We Expect A Profit From Endo International plc NASDAQ:ENDP?

2019-10-02 17:00:00 | Endo to Announce Third-Quarter 2019 Financial Results

2019-10-02 12:41:50 | The Market Tells Opioid Drugmakers to Settle Up

2019-10-01 17:02:38 | Opioid makers, distributors face shaky future as legal woes mount

2019-10-01 10:13:47 | Opioid Makers Gain on View They’ll Use Purdue Deal as Model

2019-10-01 08:46:12 | Mallinckrodt Up on Settlement Agreement With Ohio Counties

2019-09-30 20:43:07 | Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits: WSJ

2019-09-30 20:38:40 | UPDATE 1-Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits -WSJ

2019-09-30 07:30:00 | Endo Announces Successful Culmination of Litigation Regarding FDA Compounding Policy

2019-09-27 06:38:00 | Endo International's Generic Wilson's Disease Drug Gets FDA Approval

2019-09-24 08:48:12 | Mallinckrodt's StrataGraft Tissue Phase III Data Positive

2019-09-16 15:14:19 | OxyContin maker Purdue Pharma files for bankruptcy

2019-09-16 09:33:00 | Mallinckrodt and Other Opioid Stocks Are Falling After Purdue Pharma Announced Its Bankruptcy

2019-09-11 16:06:23 | Francis Chou's Chou Europe Fund Semi-Annual 2019 Commentary

2019-09-11 12:13:04 | Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up

2019-09-10 16:21:49 | Francis Chou's Chou Associates Fund Semi-Annual 2019 Letter

2019-09-10 04:56:08 | Endo Files BLA for CCH With the FDA for Cellulite Candidate Revised

2019-09-09 17:28:09 | Mallinckrodt MNK to Resolve Opioid Cases with Ohio Counties

2019-09-09 09:50:01 | Endo International Files BLA for Label Expansion of Xiaflex

2019-09-06 16:31:00 | Why DocuSign, Endo International, and Guidewire Software Jumped Today

2019-09-06 11:55:38 | Opioid Crisis Fallout Earns Short-Sellers an $880 Million Payday

2019-09-06 11:52:57 | Why Endo International Stock Is Soaring Today

2019-09-06 10:07:00 | Endo Announces Submission of Biologics License Application to FDA for Collagenase Clostridium Histolyticum CCH in Patients with Cellulite

2019-09-06 08:08:12 | Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation